ホーム >> 医療関係者ホーム >> 関連文献紹介

関連文献紹介

製品情報概要・添付文書・使用上の注意改訂のお知らせ・使用上の注意解説・インタビューフォーム等で記述のある文献をご紹介いたします。
詳しくはノバルティスダイレクト（電話：0120-003-293）へご連絡ください。

慢性骨髄性白血病

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Druker B.J. et al.: Nat. Med. 2(5)561-566, 1996 [GLIM00002]

CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells exprssing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins

Carroll M. et al.: Blood 90(12)4947-4952, 1997 [GLIM00005]

The tyrosine kinase inhibitor CGP 57148B selectively inhibits the growth of BCR-ABL-possitive cells

Deininger M.W.N. et al.: Blood 90(9)3691-3698, 1997 [GLIM00004]

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

le Coutre P. et al.: J. Natl. Cancer Inst. 91(2)163-168, 1999 [GLIM00080]

CGP 57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs

Fang G. et al.: Blood 96(6)2246-2253, 2000 [GLIM00148]

The tyrosine kinase inhibitor CGP 57148 (STI571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X

Oetzel C. et al.: Clin. Res. 6(5)1958-1968, 2000 [GLIM00014]

Favorable therapeutic index of a p210BCR-ABL-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors

Kasper B. et al.: Cancer Chemother. Pharmacol. 44(5)433-438, 1999

Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148

Dan S. et al.: Cell Death Differ. 5(8)710-715, 1998 [GLIM00012]

Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP 57148)

Beran M. et al.: Clin. Cancer Res. 4(7)1661-1672, 1998 [GLIM00008]

Inhibition of the ABL kinase activity blockes the proliferation of BCR/ABL+ Leukemic cells and induces apoptosis

Gambacorti-Passerini C. et al.: Blood Cells Mol. Dis. 23(3)380-394, 1997 [GLIM00006]

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloind Leukemia

Druker B.J.et.al.: N.Engl.J.Med.344(14),1031-1037,2001 [GLIM00153]

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

Druker B.J.et.al.: N.Engl.J.Med.344(14),1038-1042,2001 [GLIM00154]

CGP57148B(STI-571)induces differentiation and apoptosis and sepositive human leukemia cells to apoptosis due to antileukemic drug

Fang,G.et.al.:Blood96(6)2446-2253,2000 [GLIM00148]

ページの先頭に戻る

KIT(CD117)陽性消化管間質腫瘍

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Demetri G.D. et al.:New England Journal of Medicine347(7),472-480,2002 [GLIM00607]

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study
(European Organisation for Research and Treatment of
Cancer Soft Tissue and Bone Sarcoma Group)

Van Oosterom A.T. et al.: Lancet 358(9291),1421-1423,2001 [GLIM00344]

Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor

Heinrich M.C. et al.: Blood 96(3):925-932,2000 [GLIM00156]

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications

Tuveson D.A. et al.: Oncogene 20 (36):5054-5058,2001 [GLIM00261]